Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Schrödinger is trading near 52-week lows, prompting a fresh analysis. Learn more about SDGR stock and the complexities of its ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.